DSGN

Company Overview — What Does Design Therapeutics, Inc. Do?

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. Design Therapeutics, Inc. (DSGN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joao Siffert and employs approximately 40 people. With a market capitalization of $679M, DSGN is one of the notable companies in the Healthcare sector.

Design Therapeutics, Inc. (DSGN) Stock Rating — Hold (April 2026)

As of April 2026, Design Therapeutics, Inc. receives a Hold rating with a composite score of 35.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DSGN ranks #1,404 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Design Therapeutics, Inc. ranks #115 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DSGN Stock Price and 52-Week Range

Design Therapeutics, Inc. (DSGN) currently trades at $12.40. The stock lost $0.09 (0.7%) in the most recent trading session. The 52-week high for DSGN is $11.23, which means the stock is currently trading 10.4% from its annual peak. The 52-week low is $2.60, putting the stock 376.9% above its annual trough. Recent trading volume was 194K shares, suggesting relatively thin trading activity.

Is DSGN Overvalued or Undervalued? — Valuation Analysis

Design Therapeutics, Inc. (DSGN) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.55x, versus the sector average of 2.75x.

At current multiples, Design Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Design Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Design Therapeutics, Inc. (DSGN) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DSGN Debt, Balance Sheet, and Financial Health

Design Therapeutics, Inc. has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 17.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $15M.

DSGN has a beta of 1.06, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Design Therapeutics, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Design Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Design Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.22. Net income for the quarter was $-67M. Operating income came in at $-78M.

In FY 2025, Design Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.22. Net income for the quarter was $-70M. Operating income came in at $-79M.

In Q3 2025, Design Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-17M. Operating income came in at $-19M.

In Q2 2025, Design Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-19M. Operating income came in at $-22M.

Over the past 8 quarters, Design Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DSGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DSGN Dividend Yield and Income Analysis

Design Therapeutics, Inc. (DSGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DSGN Momentum and Technical Analysis Profile

Design Therapeutics, Inc. (DSGN) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

DSGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Design Therapeutics, Inc. (DSGN) ranks #115 out of 838 stocks based on the Blank Capital composite score. This places DSGN in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DSGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DSGN vs S&P 500 (SPY) comparison to assess how Design Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

DSGN Next Earnings Date

No upcoming earnings date has been announced for Design Therapeutics, Inc. (DSGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DSGN? — Investment Thesis Summary

Design Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 26/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 36/100) increases portfolio risk.

In summary, Design Therapeutics, Inc. (DSGN) earns a Hold rating with a composite score of 35.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DSGN stock.

Related Resources for DSGN Investors

Explore more research and tools: DSGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DSGN head-to-head with peers: DSGN vs AZN, DSGN vs SLGL, DSGN vs VMD.